Replimune Group Inc (REPL)
6.98
+0.42
(+6.32%)
USD |
NASDAQ |
May 03, 10:38
Replimune Group Cash from Investing (TTM): 51.25M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 51.25M |
September 30, 2023 | -127.81M |
June 30, 2023 | -140.46M |
March 31, 2023 | -142.50M |
December 31, 2022 | -124.08M |
September 30, 2022 | -12.40M |
June 30, 2022 | -23.48M |
March 31, 2022 | -1.806M |
December 31, 2021 | -123.75M |
September 30, 2021 | -78.91M |
June 30, 2021 | -112.66M |
March 31, 2021 | -188.78M |
Date | Value |
---|---|
December 31, 2020 | -54.66M |
September 30, 2020 | -151.29M |
June 30, 2020 | -81.17M |
March 31, 2020 | -5.233M |
December 31, 2019 | -2.60M |
September 30, 2019 | 66.41M |
June 30, 2019 | -44.02M |
March 31, 2019 | -65.94M |
December 31, 2018 | -94.49M |
September 30, 2018 | -124.13M |
June 30, 2018 | -39.12M |
March 31, 2018 | -44.05M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-188.78M
Minimum
Mar 2021
66.41M
Maximum
Sep 2019
-68.31M
Average
-78.91M
Median
Sep 2021
Cash from Investing (TTM) Benchmarks
Esperion Therapeutics Inc | 42.50M |
Gossamer Bio Inc | -110.97M |
NovaBay Pharmaceuticals Inc | -0.019M |
Palatin Technologies Inc | 9.293M |
iBio Inc | 8.285M |